Abstract:Abstract Introduction Restless legs syndrome (RLS) is a common disorder of unpleasant sensations during inactivity, an urge to move the legs, and hyperarousal. The pathophysiology is incompletely understood. Treatments are not always successful or carry side effects. Methods (Case Report) Results A 45-year-old woman presented with over a decade of RLS and sleep-onset insomnia. The diagnosis was based on the International RLS Study Group criteria. The severity was assessed by the nightly occurrence and Insomnia Severity Index (ISI) of 25. Interfering neurologic or sleep disorders, medications, and abnormal blood work were ruled out. Different dopamine agonists resulted in augmentation. Caffeine was stopped. Polysomnography revealed periodic limb movement with sleep fragmentation. Gabapentin was partially effective and poorly tolerated at high doses, but continued at 600 mg. While using Dextromethorphan (DXM) for an upper respiratory infection, the patient found dramatic improvement of her RLS symptoms. Independently, she discontinued Gabapentin, and continued DXM 30 mg for 6 months, with consistent improvement. ISI decreased to 10. Ultimately, considering its expense, DXM was tapered, and Tramadol initiated. The pathophysiology of RLS is partially understood. Studies showed abnormalities in iron regulation, low adenosine tone, enhanced glutamatergic activity, inflammation, and a genetic predisposition, as contributing factors. Alpha-2-delta calcium channel ligands inhibit the presynaptic glutamate release. Central nervous system iron deficiency may increase glutamatergic tone. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, inhibits the activation of NMDA receptor by glutamate and decreases glutamate presynaptic release. Ketamine was reported to effectively treat RLS. DXM, another NMDA receptor antagonist, has not been reported to treat RLS in the literature. Additionally, an association between inflammation and RLS was described, and limited data showed anti-inflammatory effect of DXM. Conclusion Patients with RLS suffer from their symptoms’ burden. Approved medications could carry side effects, or augmentation. We report a case of severe RLS with dramatic and sustained improvement with DXM. Support (if any)

Suspected duloxetine-induced restless legs syndrome phenotypic variant: a case report

[Restless Legs Syndrome in Ischemic Stroke Patients: Clinical Features and Significance].

Anticonvulsant Agents for Treatment of Restless Legs Syndrome

Challenges in the Treatment of Restless Legs Syndrome: A Case Report

0706 Dextromethorphan for Restless Legs Syndrome: Testing the Glutamate Theory

Sensory Aspects of Restless Legs Syndrome: clinical, neurophysiological and neuroimaging prospectives.

Treating Severe Refractory and Augmented Restless Legs Syndrome

Restless legs syndrome symptoms in primary care: a prevalence study

Time to REST: epidemiology and burden

Restless legs syndrome/Willis Ekbom disease: Evaluation and treatment

[Restless legs syndrome, periodic limb movements, and psychopharmacology]

Restless legs syndrome. Pathophysiology, diagnosis and treatment

[Epidemiology of restless legs syndrome]

Identification of Causal Genes and Potential Drug Targets for Restless Legs Syndrome: A Comprehensive Mendelian Randomization Study

Rethinking clinical trials in restless legs syndrome: A roadmap

Restless Back Syndrome: A Case Report and Literature Review

Current and emerging pharmaceutical strategies for the treatment and management of restless legs syndrome

Case report: A new treatment for restless leg syndrome: three cases

Effect of "He Tiao Du Ren An Shen Acupuncture" on restless leg syndrome: A randomized trial

Augmentation in patients with restless legs syndrome receiving pramipexole therapy: a retrospective study in a single center from China

Restless Legs Syndrome: an Early Clinical Feature of Parkinson Disease in Men